Biogen Inc.Â BIIB announced that it plans to initiate a global phase IV study on its spinal muscular atrophy (SMA) drug Spinraza (nusinersen).Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.1% per year.These 7 were selected because of their superior potential for immediate breakout.